What changed: Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)

When this page itself was last checked or edited.

Active surveillance if asymptomatic and stable; sirolimus for progressive or symptomatic disease; surgery or liver transplant for isolated hepatic disease.

Surveillance first, sirolimus for progression (ESMO Open).

Neuroendocrine cohort: about one in four responded, concentrated in high-grade disease; angiosarcoma cohort about one in four, mostly cutaneous scalp and face tumours; many other cohorts inactive.

Florou and colleagues; later confirmed in the DART SWOG S1609 angiosarcoma cohort (2021).

Tanas and colleagues, Sci Transl Med; Errani and colleagues.

Penel and colleagues, JCO, phase 2.

Léauté-Labrèze and colleagues, NEJM: serendipitous discovery.

A milestone in how this cancer is treated.

A milestone in how this cancer is treated.